
Advertise on podcast: PEPtalk
Rating
5from
This podcast has
15 episodes
Language
EnglishPublisher
Jake & CynthiaExplicit
No
Date created
2026/09/30
Latest episode
2026/11/13
Average duration
12 min.
Release period
4 days
Description
A twice-weekly, AI-hosted podcast on the peptide market. Mondays: deep dives — a fast pulse on the big GLP-1 names plus one molecule unpacked in full. Fridays: the week in review — the biggest stories from the lab, the market, and the regulators, all in about fifteen minutes. Hosted by Jake and Cynthia. For research and informational purposes only — not medical advice.
Unlock PEPtalk podcast Email contact info,
Listeners & Audience details
Email contact information
Direct podcast contact details

Listeners
Audience numbers & engagement insights

Audience details
Podcast Insights

Podcast episodes
Check latest episodes from PEPtalk podcast
Peptalk Week in Review — November 13, 2026
2026/11/13
This week: the week's biggest story — the FDA orders a class-wide label warning on every GLP-1 drug, from Ozempic to Zepbound, over a rare eye condition, NAION: about 6.4 cases per 100,000 person-years on a GLP-1 against 3.8 on comparison treatments in 126 pooled trials, a small absolute risk with a serious consequence.
Plus: the HHS peptide-compounding policy moves from paper to practice as Olympia Pharmaceuticals starts compounding BPC-157 for patients with a prescription, with the public comment window closing November 13 and state pharmacy boards pushing back;
Pfizer lands up to $1.5 billion from Blackstone to fund ten Phase 3 trials of its once-monthly GLP-1 shot Berobenatide, with first approvals targeted for 2028;
China approves Lilly's Orforglipron (Foundayo), the first GLP-1 weight-loss pill in the country, ahead of Novo's oral Wegovy.
And quick hits on Health Canada seizing 11,400+ vials of contaminated unauthorized peptides, Pemvidutide's Phase 2 results in alcohol use disorder, and ObesityWeek opening November 14.
For research and informational purposes only — not medical advice. Nothing on this show is a recommendation for any product or treatment.
Sources:
• U.S. Food and Drug Administration, Drug Safety Communication (Nov 9, 2026) — FDA requires safety labeling changes for GLP-1 receptor agonists due to potential increased risk of NAION (126 randomized trials, 134,253 patients, 15 probable NAION events; 6.4 vs 3.8 per 100,000 person-years): https://www.fda.gov/drugs/drug-safety-communications/fda-requires-safety-labeling-changes-glucagon-peptide-1-receptor-agonists-glp-1-ras-due-potential
• Pharmaceutical Executive (Nov 10, 2026) — FDA requests updated safety label warning across all GLP-1 receptor agonists for potential risk of NAION: https://www.pharmexec.com/view/fda-requests-safety-label-warning-glp-1-receptor-agonist-risk-naion
• Olympia Pharmaceuticals, GlobeNewswire (Nov 12, 2026) — Olympia Pharmaceuticals to compound select peptides under HHS interim enforcement policy (503A pharmacy; BPC-157 first, then KPV, TB-500, MOTS-c, Semax, Epitalon; available by December; licensed in 49 states): https://rss.globenewswire.com/news-release/2026/11/12/3401699/0/en/olympia-pharmaceuticals-to-compound-select-peptides-under-hhs-interim-enforcement-policy.html
• Federal Register, Doc. 2026-22192 (Docket HHS-OASH-2026-0496) — HHS enforcement discretion policy for 503A compounding of six peptides; public comment closes November 13, 2026: https://www.federalregister.gov/documents/2026/10/30/2026-22192/enforcement-discretion-policy-regarding-503a-compounding-using-certain-peptide-bulk-drug-substances
• Reuters (Nov 11, 2026) — Pfizer secures up to $1.5 billion from Blackstone for obesity drug development (Berobenatide, once-monthly GLP-1; 10 Phase 3 trials; first approvals targeted 2028; Metsera acquisition up to $10 billion): https://www.reuters.com/business/healthcare-pharmaceuticals/pfizer-secures-up-15-billion-blackstone-obesity-drug-development-2026-11-11/
• BioPharma Dive (Nov 12, 2026) — Blackstone bets $1.5B on Pfizer's obesity drug: https://www.biopharmadive.com/news/blackstone-pfizer-berobenatide-deal/874483/
• Reuters (Nov 12, 2026) — Eli Lilly becomes first drugmaker to have a GLP-1 weight-loss pill approved in China (Orforglipron / Foundayo; first oral GLP-1 weight-loss pill approved in China; Novo's oral Wegovy application pending): https://wnflsports.com/2026/11/12/china-approves-eli-lillys-weight-loss-pill-orforglipron/
• Health Canada, public advisory RA-82930 (Nov 6, 2026) — Health Canada warns about contaminated unauthorized injectable peptides and non-peptide drugs (11,400+ vials seized from Shanghai ERP Peptide Biotechnology Co. Ltd. and two Canadian online retailers; bacteria including Acinetobacter seifertii, Acinetobacter nosocomialis, Cutibacterium acnes): https://recalls-rappels.canada.ca/en/alert-recall/health-canada-warns-about-contaminated-unauthorized-injectable-peptides-and-non
• Health Canada, public advisory (Nov 12, 2026) — Health Canada warns about unauthorized peptides, including contaminated injectable peptides sold by Sage & Summit Wellness Co. in Ottawa, ON: https://www.newswire.ca/news-releases/public-advisory-health-canada-warns-about-unauthorized-peptides-including-contaminated-injectable-peptides-sold-by-sage-amp-summit-wellness-co-in-ottawa-on-802173243.html
• Altimmune, GlobeNewswire (Nov 9, 2026) — Altimmune reports positive Phase 2 RECLAIM results for Pemvidutide in alcohol use disorder (heavy drinking days −4.20/week vs −2.75 placebo; 42.2% with zero heavy drinking days vs 17.4% placebo; ~100 adults; presented at AASLD The Liver Meeting 2026, Denver; end-of-Phase 2 FDA meeting planned December 2026): https://www.quiverquant.com/news/Altimmune%20Reports%20Positive%20Phase%202%20RECLAIM%20Results%20for%20Pemvidutide%20in%20Alcohol%20Use%20Disorder%20and%20Announces%20FDA%20Meeting%20Plans%20for%20Phase%203%20Program
A Spoke-Media production:
https://www.spoke-media.com
14: Peptalk Deep Dive — GHK-Cu
2026/11/09
The copper peptide in half the serums on your shelf. GHK-Cu is a naturally occurring copper peptide your body already makes — levels highest when you're young, declining with age.
This week Jake and Cynthia unpack what it is, what the research actually shows for skin, wound healing, hair, and joints, and why the same molecule gets three different regulatory answers depending on the product.
GLP pulse: Lilly and Hims & Hers strike a direct-sales deal for Zepbound and Foundayo at LillyDirect cash prices — and Hims contractually closes the door on compounded copies of Lilly's GLP-1s.
Retatrutide posts knee osteoarthritis results from two Phase 3 trials in the New England Journal of Medicine. And the Wegovy pill passes 100,000 prescriptions in its first two months — growing the whole GLP-1 pie instead of cannibalizing it.
Deep dive: GHK-Cu's proposed mechanism (collagen and elastin, blood-vessel growth, antioxidant and anti-inflammatory effects), the small human studies behind the skin claims, the 2023 diabetic-mouse wound study, the single small 2013 hair study, and the evidence gap everywhere else.
Plus the safety picture — topicals usually well tolerated, injectables carrying the highest risk — and the FDA's route split: non-injectable compounded GHK-Cu in Category 1 since May 14, 2026 (enforcement policy, not approval), injectable GHK-Cu with its nomination withdrawn and an FDA immunogenicity warning, and GHK-Cu absent from the HHS draft peptide policy's six names.
Next Monday: KPV, the standalone peptide — then the KLOW versus GLOW comparison on November 23, where GHK-Cu returns as one of four.
Everything we discuss is for research and informational purposes only. Not medical advice.
Sources:
- GoodRx, "GHK-Cu for Skin, Hair, and Healing: What Does the Research Show?" by Patricia Pinto-Garcia, MD, MPH, medically reviewed by Sophie Vergnaud, MD, published November 2, 2026 — https://www.goodrx.com/health-topic/peptides/what-is-ghk-cu
- DPS Law, "Is GHK-Cu (Copper Peptide) Legal? 2026 Status," November 2, 2026 — https://dpslaw.com/insights/is-ghk-cu-legal
- U.S. Food and Drug Administration, "Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act," updated May 14, 2026 — https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-nominated-use-compounding-under-section-503a-federal-food-drug-and
- U.S. Department of Health and Human Services, "Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances," 91 FR 68526 (October 30, 2026)
- Eli Lilly / PR Newswire via Morningstar, "Lilly and Hims & Hers Expand Access to FDA-Approved Lilly Medicines," November 6, 2026 — https://www.morningstar.com/news/pr-newswire/20261106de90839/lilly-and-hims-hers-expand-access-to-fda-approved-lilly-medicines
- Reuters via SRN News, "Lilly to Sell Obesity Drugs Directly on Hims & Hers Site," November 6, 2026 — https://srnnews.com/lilly-to-sell-obesity-drugs-directly-on-hims-hers-site/
- MedicalXpress, "Experimental weight-loss drug eases painful knee osteoarthritis in two clinical trials," November 8, 2026 — https://medicalxpress.com/news/2026-11-experimental-weight-loss-drug-eases.html
- Jastreboff et al., "Retatrutide Once Weekly in Adults with Knee Osteoarthritis Pain and Obesity" (TRIUMPH-1), New England Journal of Medicine, 2026; TRIUMPH-4 presented at the American College of Rheumatology annual meeting, Orlando, November 2026
- Healio, "GLP-1 prescriptions for obesity have increased rapidly since introduction of Wegovy pill," November 6, 2026 — https://www.healio.com/news/primary-care/20261106/glp1-prescriptions-for-obesity-have-increased-rapidly-since-introduction-of-wegovy-pill
A Spoke-Media production:
https://www.spoke-media.com
13: Peptalk Week in Review — November 6, 2026
2026/11/06
This week: the week's biggest story — Novo Nordisk beats expectations and raises its full-year guidance, with the once-daily Wegovy pill doing DKK 5.39 billion in the quarter, about 17% ahead of forecasts, while injectable Wegovy and Ozempic both slip.
Plus: new preliminary research from the American Heart Association finds GLP-1 drugs outperformed Metformin for people with Prediabetes and obesity — 1.5x more likely to return to normal blood sugar, 31% lower risk of developing type 2 diabetes — with the observational caveats kept in frame;
Employers keep pulling GLP-1 coverage for weight loss (53%, down from 57%, the first decline in three years) while Novo partners with Andel so companies can subsidize Wegovy outside insurance at $149 a month for the pill and $199 for the injection; and quick hits on Ascletis's ObesityWeek posters and the HHS peptide-compounding comment deadline.
For research and informational purposes only — not medical advice. Nothing on this show is a recommendation for any product or treatment.
Sources:
• Novo Nordisk, Company announcement No 65 / 2026 — Financial report for the period 1 January 2026 to 30 September 2026 (Nov 4, 2026), via GlobeNewswire syndication: Q3 sales DKK 79,195m (+4% CER), adjusted operating profit DKK 31,720m (+27% CER), Wegovy pill DKK 5,394m, guidance raised to −2% to +2% at CER.
• TradingView / dpa-AFX (Nov 4, 2026) — Novo Nordisk Q3 adj. operating profit increases, obesity sales up 22%, raises 2026 outlook: https://www.tradingview.com/news/dpa_afx:73790cd8c7838:0-novo-nordisk-q3-adj-operating-profit-increases-obesity-sales-up-22-raises-2026-outlook/
• Sweden Herald (Nov 4, 2026) — Novo Nordisk beats third-quarter expectations as sales top forecasts: https://swedenherald.com/article/novo-nordisk-beats-third-quarter-expectations-as-sales-top-forecasts
• American Heart Association news release (Nov 2, 2026) — GLP-1 meds linked to lower diabetes, heart risks than standard diabetes prevention med (256,492 adults with Prediabetes and obesity; preliminary abstract presented at Scientific Sessions 2026): https://newsroom.heart.org/news/glp-1-meds-linked-to-lower-diabetes-heart-risks-than-standard-diabetes-prevention-med
• The Inference (Nov 2, 2026) — Employers are cutting GLP-1 coverage; Novo Nordisk sells Wegovy outside insurance for $149 to $199 a month (WTW survey, Marsh 2026 survey, Andel partnership Oct 28, 2026): https://theinference.org/article/employers-are-cutting-glp-1-coverage-novo-nordisk-sells-wegovy-outside-insurance-for-149-to-199-a-month
• Journalarta (Nov 4, 2026) — First GLP-1 weight-loss pill approved in Australia (Therapeutic Goods Administration): https://journalarta.com/en/2026/11/04/first-glp-1-weight-loss-pill-australia/
• Ascletis Pharma / PR Newswire via Morningstar (Nov 2, 2026) — Ascletis to present study results of oral small-molecule GIPR agonist ASC48 and GLP-1R/GIPR/GCGR triple peptide agonist ASC37 at ObesityWeek 2026: https://www.morningstar.com/news/pr-newswire/20261102cn85414/ascletis-to-present-study-results-of-oral-small-molecule-gipr-agonist-asc48-and-glp-1rgiprgcgr-triple-peptide-agonist-asc37-at-obesityweek-2026
• Federal Register, Doc. 2026-22192 (Docket HHS-OASH-2026-0496) — HHS enforcement discretion policy for 503A compounding of six peptides; public comment open until November 13, 2026: https://www.federalregister.gov/public-inspection/2026-22192/enforcement-discretion-policy-regarding-503a-compounding-using-certain-peptide-bulk-drug-substances
A Spoke-Media production:
https://www.spoke-media.com
12: Peptalk Deep Dive — Wolverine stack
2026/11/02
Two peptides, two halves of the same repair job. BPC-157 builds blood supply locally; TB-500 mobilizes repair cells systemically. Together they're the Wolverine stack — the most talked-about combination in the peptide world, and one with no human trials behind it.
In this episode:
• GLP pulse: a federal judge declines to block Lilly's Zepbound and Mounjaro ads in Novo Nordisk's false-advertising suit — what the ruling does and doesn't decide — plus fresh oral prescription numbers from the Fierce Pharma tracker.
• The deep dive: how BPC-157 and TB-500 each work, why the community pairs them, and what the animal evidence actually shows.
• The news: the HHS interim compounding policy meets the market — Superpower opens pre-orders for compounded BPC-157, TB-500, and MOTS-c, and the public comment window closes November 13.
• The catch: the policy covers one peptide per product, so a combined Wolverine vial falls outside it. Plus the sports ban, the evidence gap, and what's next (GHK-Cu, Monday November 9).
Everything we discuss is for research and informational purposes only. Not medical advice.
Sources:
• AminoWire, "Superpower opens compounded peptide pre-orders after HHS notice," October 31, 2026 — https://aminowire.news/news/2026/10/superpower-compounded-peptides-preorders/
• Thomson Reuters, "US judge refuses to block Eli Lilly weight-loss drug ads, rules against Novo Nordisk," October 26, 2026 — https://krro.com/2026/10/26/us-judge-lets-eli-lilly-continue-ads-for-weight-loss-drugs-rules-against-novo-nordisk/
• Fierce Pharma, Oral GLP-1 Tracker (updated October 30, 2026) — https://www.fiercepharma.com/pharma/oral-glp-1-tracker-launch-trajectories-lilly-foundayo-novo-wegovy-pill
• HHS interim enforcement-discretion policy on 503A compounding of six peptides, Federal Register Doc. 2026-22192, 91 FR 68526-68527 (published October 30, 2026); public comments due November 13, 2026, docket HHS-OASH-2026-0496
• National Community Pharmacists Association, "FDA grants enforcement discretion to compounding six peptides," October 29, 2026 — https://ncpa.org/newsroom/qam/2026/10/29/fda-grants-enforcement-discretion-compounding-six-peptides
• Healthline, "What's the Wolverine Peptide Stack and Is It Safe?" — https://www.healthline.com/health/wolverine-peptides
• BPC-157 systematic review (2025): 39 studies, 1993-2024, presented at the American Academy of Orthopaedic Surgeons
• TB-500 Achilles tendon study (2026): 32 rats, systemic treatment, load-to-failure significance; Philp et al. (2003) angiogenesis; Bock-Marquette et al., Nature (2004) cardiac repair
• FDA Pharmacy Compounding Advisory Committee, July 23-24, 2026: BPC-157 and TB-500 favorable recommendations (8-6-1), advisory only
A Spoke-Media production:
https://www.spoke-media.com
11: Peptalk Week in Review — October 30, 2026
2026/10/30
This week: the week's biggest story — HHS posts a draft enforcement-discretion policy for compounding six peptides (BPC-157, Epitalon, KPV, MOTS-c, Semax, TB-500) under section 503A, scheduled for Federal Register publication on October 30 — what it covers, what it doesn't, and where the critics stand.
Plus: Lilly's Retatrutide beats Ozempic more than two-to-one on weight loss in the Phase 3 TRANSCEND-T2D-2 head-to-head; the EY-Parthenon GLP-1 Consumer Impact Report finds 21% of US adults have now tried a GLP-1;
Lilly raises its full-year outlook on booming Mounjaro and Zepbound sales while its Foundayo pill lags estimates; and Ascletis files an IND for ASC39, an oral small-molecule amylin agonist.
For research and informational purposes only — not medical advice. Nothing on this show is a recommendation for any product or treatment.
Sources:
• Federal Register (public inspection, Doc. 2026-22192, Docket HHS-OASH-2026-0496) — Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, posted October 28, 2026, scheduled for publication October 30, 2026: https://www.federalregister.gov/public-inspection/2026-22192/enforcement-discretion-policy-regarding-503a-compounding-using-certain-peptide-bulk-drug-substances
• Reuters (Oct 28, 2026) — US health department to allow temporary sale of some unapproved peptides: https://www.reuters.com/legal/litigation/us-health-department-allow-temporary-sale-some-unapproved-peptides-2026-10-28/
• NCPA (Oct 29, 2026) — FDA grants enforcement discretion to compounding six peptides: https://ncpa.org/newsroom/qam/2026/10/29/fda-grants-enforcement-discretion-compounding-six-peptides
• AminoWire (updated Oct 28, 2026) — Peptide access policy goes to White House review; Appendix A names the six peptides: https://aminowire.news/news/2026/10/peptide-interim-access-policy-omb-review/
• Partnership for Safe Medicines (Oct 28, 2026) — Statement on the FDA and HHS enforcement discretion policy for 503A compounding: https://www.safemedicines.org/2026/10/statement-on-503a-peptide-enforcement.html
• Eli Lilly investor press release (Oct 28, 2026) — Lilly's Retatrutide delivered greater A1C reduction and more than double the weight loss of Ozempic's highest approved dose in head-to-head trial: https://investor.lilly.com/news-releases/news-release-details/lillys-retatrutide-delivered-greater-a1c-reduction-and-more
• ABC News / GMA Wellness (Oct 28, 2026) — New weight loss drug Retatrutide provides double the weight loss of Ozempic, Lilly says: https://abcnews.com/GMA/Wellness/new-weightloss-drug-retatrutide-double-weight-loss-ozempic/story?id=137614872
• EY-Parthenon GLP-1 Consumer Impact Report (released Oct 22, 2026): https://www.ey.com/en_us/newsroom/2026/10/glp-1-consumer-impact-report
• Food Business News (Oct 2026) — Snack consumption squeezed by surging GLP-1 adoption (21% of US adults have tried GLP-1s, up from 8% in 2024): https://www.foodbusinessnews.net/articles/31233-snack-consumption-squeezed-by-surging-glp-1-adoption
• Reuters (Oct 29, 2026) — Eli Lilly lifts revenue outlook on weight-loss drug sales, trims profit view on deal charges: https://www.reuters.com/business/healthcare-pharmaceuticals/eli-lilly-lifts-revenue-outlook-weight-loss-drug-sales-trims-profit-view-deal-2026-10-29/
• Stocktwits (Oct 28, 2026) — HIMS stock jumps 5% after HHS temporarily clears compounding of six peptides: https://stocktwits.com/news-articles/markets/equity/hims-stock-jumps-5-after-hhs-temporarily-clears-compounding-of-six-peptides/cZU9rvnR9Gn
• Ascletis Pharma / PR Newswire (Oct 25, 2026) — Ascletis announces FDA IND submission of ASC39, an oral small molecule selective amylin receptor agonist: https://www.morningstar.com/news/pr-newswire/20261025cn79691/ascletis-announces-fda-ind-submission-of-asc39-an-oral-small-molecule-selective-amylin-receptor-agonist-for-the-treatment-of-obesity
A Spoke-Media production:
https://www.spoke-media.com
10: Peptalk Deep Dive - TB-500
2026/10/26
This week: TB-500, the systemic half of the Wolverine stack — a synthetic fragment of thymosin beta-4, a 43-amino-acid protein found in almost every cell in the human body.
Jake and Cynthia unpack the mechanism (G-actin binding, cell migration, angiogenesis, the ILK-Akt survival pathway, anti-inflammatory signaling), the animal research on tendons, ligaments, heart and lung repair, the real evidence gap (encouraging reports, yet to be proven in human trials), the July 2026 FDA advisory vote, and why it's banned in sport. Plus a refreshed GLP pulse: the October 23 Pharmafile report on the indirect comparison of Lilly's oral Foundayo (orforglipron) against oral semaglutide; the latest oral GLP-1 prescription tracker; and Novo's new CagriSema analyses in women from the REDEFINE 1 trial.
For research and informational purposes only — not medical advice. Nothing on this show is a recommendation for any product or treatment.
Sources:
- Pharmafile (Oct 23, 2026) — Orforglipron shows weight and glucose advantages over oral semaglutide in indirect comparison (ACHIEVE-3 vs PIONEER-PLUS, 52 weeks; 1.46 points greater weight reduction, 0.31 points greater HbA1c reduction; indirect comparison, not head-to-head): https://pharmafile.com/news/orforglipron-shows-weight-and-glucose-advantages-over-oral-semaglutide-in-indirect-comparison/
- Fierce Pharma (updated Oct 23, 2026) — The Oral GLP-1 Tracker: Novo's Wegovy pill vs Lilly's Foundayo (Wegovy pill ~173K prescriptions, Foundayo ~58K, down ~4% week over week; Novo ~75% of oral pill market, Lilly over 25%): https://www.fiercepharma.com/pharma/oral-glp-1-tracker-launch-trajectories-lilly-foundayo-novo-wegovy-pill
- Reuters (Oct 20, 2026) — Novo's CagriSema helped women lose 25% of weight on average, analysis shows (REDEFINE 1: 25.0% mean weight loss at 68 weeks in 2,309 women vs 3.0% placebo; 26.7% / 24.8% / 23.1% across menopause stages; post hoc analyses, hypothesis-generating): https://dukecountry.fm/2026/10/20/novos-cagrisema-helped-women-lose-25-of-weight-on-average-analysis-shows/
- HealingMaps — TB-500 (thymosin beta-4 fragment) explainer: mechanism, WADA status, PCAC review: https://healingmaps.com/tb-500-thymosin-beta-4-fragment-wound-healing-peptide/
- PrimeLab Peptides — TB-500 tendon and ligament repair evidence (2026 rat Achilles study; 2013 rat MCL model): https://primelabpeptides.com/blogs/news/what-evidence-shows-tb-500-effectiveness-in-tendon-and-ligament-repair-post-injury
- PrimeLab Peptides — TB-500 and fibrosis/scar tissue (cardiac, lung fibrosis models): https://primelabpeptides.com/blogs/news/what-evidence-supports-tb-500-use-in-pulmonary-fibrosis-research
- Paragon Sports Medicine — TB-500 regulatory position, WADA S2 prohibition, 503A status: https://www.paragonsportsmedicine.com/peptides/tb-500
- TarzanOptimized — What is TB-500 (thymosin beta-4 fragment, systemic vs local repair): https://tarzanoptimized.com/blog/what-is-tb-500
- Frier Levitt — July 23–24, 2026 PCAC votes: six of seven peptides recommended for 503A Bulks List (TB-500 8–6): https://www.frierlevitt.com/news/fda-pcac-peptides-503a-compounding/
- Flow Wellness — July 2026 PCAC update: what the vote means and does not mean: https://flowwellness.com/new-peptides-may-be-available-soon/
- Impact Health Clinics — BPC-157/TB-500 FDA status: the July 2026 review, votes by substance: https://www.impacthealthclinics.com/blog/bpc-157-fda-status-2026
- Business Wire — Enhanced: PCAC vote context, Wolverine Stack (BPC-157 + TB-500) protocol: https://www.businesswire.com/news/home/20260727193803/en/Enhanced-Applauds-FDA-Advisory-Committees-Landmark-Vote-to-Expand-Legal-Compounding-Pathway-for-Peptides
Filed to the library as 010, and with that filing Sunday's Monday-production run now stands down for this slot — the weekly series itself is untouched.
A Spoke-Media production:
https://www.spoke-media.com
9: Peptalk Week in Review — October 23, 2026
2026/10/23
TOP STORY: Health Secretary Robert F. Kennedy Jr. says the Trump administration aims to create a regulated marketplace for peptides — "Americans are going to be buying these anyway. Our objective was to make sure that there is a regulated marketplace, so that what they're getting is what they claim to be, that is safe, that the factories are inspected." The sequel to the FDA's compounding-access policy story.
ACCESS VS. SAFETY: Apothecary Pharma's nationwide recall grows to 23 vials of compounded Tirzepatide plus one vial of NAD+ injection (Class II, no reported illnesses); Carolina Infusion's Class II recall of compounded Semaglutide, Tirzepatide, and Sermorelin syringes; an FDA warning letter to Empower Pharmacy; twenty state attorneys general warn about Chinese GLP-1 ingredients entering through the FDA's "Green List"; South Africa moves to tighten its compounding rules.
CONSUMER ECONOMICS: the GLP-1 supplement boom — a $74 billion market with no FDA preapproval requirement; plus one-liners on New Zealand premium food exports and GLP-1 costs vs. retirement savings.
PIPELINE: Ascletis posts positive preclinical data for a once-weekly oral amylin peptide pipeline; WuXi AppTec on why oral peptides can require 10–100x the drug ingredient.
BENEFITS RESEARCH: GLP-1 users with sleep apnea showed ~40% lower risk of acute respiratory failure (presented at CHEST 2026, not yet peer-reviewed).
For research and informational purposes only — not medical advice.
Sources:
- Reuters — "Kennedy says Trump administration aims for regulated market for peptides" (Oct 20, 2026): https://www.reuters.com/world/kennedy-says-trump-administration-aims-regulated-market-peptides-2026-10-20/
- Fox Business — Apothecary Pharma recall update, 23 vials incl. NAD+ injection (Oct 21, 2026)
- USA Today — "GLP-1 injections nationwide recall" (Oct 19, 2026): https://www.usatoday.com/story/money/consumer-protection/recalls-alerts/2026/10/19/glp-1-injections-nationwide-recall/92332991007/
- MedShadow — FDA Enforcement Report: Carolina Infusion compounded GLP-1 recalls (Oct 16, 2026): https://medshadow.org/drug-updates-recalls/fda-recalls-and-warnings/compounded-glp1-recalls-metoclopramide-tretinoin/
- FDA warning letter to Empower Pharmacy (dated Sept 18, 2026; public Sept 22, 2026)
- Regulatory Oversight / AL AG release — 20-state AGs letter on FDA "Green List" and Chinese GLP-1 ingredients (Oct 21, 2026)
- Reuters — "South Africa revises rules around customisation of weight-loss drugs" (Oct 14, 2026): https://www.reuters.com/legal/litigation/south-africa-revises-rules-around-customisation-weight-loss-drugs-2026-10-14/
- Reuters — "Weight-loss drug users turn to dietary supplements; doctors, regulators raise flags" (Oct 20, 2026): https://www.reuters.com/legal/litigation/weight-loss-drug-users-turn-dietary-supplements-doctors-regulators-raise-flags-2026-10-20/
- RNZ — "Rise of GLP-1 unlocking new opportunities for New Zealand's premium food exports" (Oct 19, 2026): https://www.rnz.co.nz/news/country/2036071/rise-of-glp-1-unlocking-new-opportunities-for-new-zealand-s-premium-food-exports
- Benefit News / Nationwide Retirement Institute survey — GLP-1 costs vs. retirement savings (Oct 21, 2026)
- PR Newswire via Morningstar — "Ascletis announces positive preclinical data for the most comprehensive once-weekly oral peptide pipeline" (Oct 19, 2026): https://www.morningstar.com/news/pr-newswire/20261019cn75171/ascletis-announces-positive-preclinical-data-for-the-most-comprehensive-once-weekly-oral-peptide-pipeline-for-the-treatment-of-obesity
- GlobeNewswire — "Peptide manufacturing trends: how oral dosing raises API demand" (WuXi AppTec, Oct 21, 2026): https://www.globenewswire.com/news-release/2026/10/21/3385365/0/en/peptide-manufacturing-trends-how-oral-dosing-raises-api-demand.html
- Medical Daily — "GLP-1, sleep apnea, acute respiratory failure" (CHEST 2026 presentation, Oct 19, 2026): https://www.medicaldaily.com/glp-1-sleep-apnea-acute-respiratory-failure-chest-2026-480137
A Spoke-Media production:
https://www.spoke-media.com
8: Bonus Episode: “Peptides” explained
2026/10/21
Peptide Overview:
A comprehensive walkthrough of "Peptides: small wonder?", the expert view published by SCOR (one of the world's largest reinsurance companies).
Jake and Cynthia cover what peptides actually are, who's using them and why — from GLP-1s to BPC-157 — the four ways people obtain them, the six categories of risk, how they compare to other drugs, and what it all means in plain language. Ends with a simplified overview tying it together.
For research and informational purposes only — not medical advice.
**Sources:**
- SCOR — "Peptides: small wonder?" Expert View (September 2026): https://www.scor.com/en/expert-views/peptides-small-wonder
A Spoke-Media production:
https://www.spoke-media.com
7: Peptalk Deep Dive — BPC-157
2026/10/19
This week: BPC-157, the most talked-about healing peptide on the internet — a 15-amino-acid fragment from human gastric juice with thirty years of animal research and encouraging reports, but yet to be proven in human trials.
Jake and Cynthia unpack the mechanism (angiogenesis, fibroblast activity, gut-barrier repair), the striking tendon/ligament/gut data in animals, the real evidence gap, and the July 2026 FDA advisory vote everyone is misreading.
Plus the GLP pulse: the FDA's interim peptide-compounding policy names BPC-157, Europe's regulator backs Lilly's oral GLP-1 Foundayo, and Biomea posts Phase 1 data for its oral small-molecule BMF-650.
For research and informational purposes only — not medical advice. Nothing on this show is a recommendation for any product or treatment.
**Sources:**
- Reuters — FDA/HHS submit interim peptide-compounding policy for White House review (Oct 15): https://www.reuters.com/legal/litigation/us
-fda-takes-step-change-peptide-compounding-policy-2026-10-15/
- AP via Stocktwits — BPC-157 named in compounding policy reporting; Hims stock +6% (Oct 15): https://stocktwits.com/news-articles/markets/equity/hims-stock-peptide-hopes-trump-administration-reviews-plan-unlock-market/cZx0VkeRBr8
- EMA — CHMP recommends EU approval for Foundayo/orforglipron (Oct 16): https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-12-15-october-2026
- Reuters — Lilly's Foundayo wins European backing (Oct 16): https://www.reuters.com/legal/litigation/eli-lillys-weight-loss-pill-wins-backing-europe-2026-10-16/
- GlobeNewswire — Biomea Phase 1 results for oral small-molecule GLP-1 BMF-650 (Oct 13): https://www.globenewswire.com/news-release/2026/10/13/3380154/0/en/biomea-fusion-announces-phase-1-results-for-bmf-650-its-investigational-next-generation-oral-small-molecule-glp-1-receptor-agonist.html
- Brainflow — BPC-157 complete guide (2025 AAOS systematic review, 39 studies): https://brainflow.co/complete-guide-to-BPC-157-benefits-dosage/
- Marketing or Science — BPC-157 evidence vs hype, July 2026 PCAC vote: https://marketingorscience.com/articles/pharma/2026/07/BPC-157-healing-peptide
- Lambert Medical Practice — BPC-157 peptide guide (mechanisms, gut/tendon data): https://lambertmedicalpractice.co.uk/blog/BPC-157-peptide-guide/
- Top Doctor Magazine — PCAC vote 8–6, ulcerative colitis indication: https://topdoctormagazine.com/news/regenerative-medicine-peptide-evidence-hype/
- OneDayMD — clinician peptide guide (PCAC six-of-seven, regulatory status): https://www.onedaymd.com/2026/02/peptides-guide.html
- Frier Levitt — PCAC 503A legal analysis (advisory vs binding): https://www.frierlevitt.com/news/fda-pcac-peptides-503a-compounding/
- Blog by Donna — PCAC vote explainer ("recommendation is not a rule"): https://blogbydonna.com/the-fda-peptide-vote-didnt-legalize-BPC-157/
A Spoke-Media production:
https://www.spoke-media.com
6: Peptalk Week in Review — October 16, 2026
2026/10/16
This week the biggest story isn't a trial readout — it's the economy reshaping itself around GLP-1s.
Jake and Cynthia unpack Gallup's new numbers (15% of US adults have tried a GLP-1 for weight loss, up from 3% two years ago), the Cornell grocery-receipts study (household spending down 5.3%, savory snacks down 10%), and the BCG survey (active users spending 11% more on high-protein foods). Plus the industry response: Olive Garden's Lighter Portions menu, Nestlé's GLP-1 nutrition line, and Walmart covering Ozempic and Mounjaro at zero cost for employees with type 2 diabetes in 2027.
Also: a Blood Cancer Journal study of 140,000 matched patients finds no blood-cancer risk signal from GLP-1s.
Semaglutide extends lifespan 12% in mice (Nature); Pharma's GLP-1 brain-drug pipeline heats up with Lilly's Brenipatide for alcohol use disorder; and the amylin wave builds with Petrelintide (10.7%), Survodutide (13.1%), and Trevogrumab's 70% muscle-loss prevention.
For research and informational purposes only — not medical advice.
**Sources:**
- Gallup — GLP-1 usage reaches new high (15% ever-used, 11% current; May–June 2026 survey): https://news.gallup.com/poll/712157/glp-usage-reaches-new-high.aspx
- Medical Xpress — Cornell/Journal of Marketing Research grocery spending study (Dec 2025): https://medicalxpress.com/news/2025-12-ozempic-foods-americans-buy.html
- Green Queen — BCG GLP-1 food consumption survey (+11% protein, +15% fruit/veg): https://www.greenqueen.com.hk/boston-consulting-group-glp-1-food-consumption-spending-protein-fiber-survey/
- Yahoo Lifestyle — Olive Garden "Lighter Portions" menu, GLP-1 users cited (Oct 13, 2026): https://www.yahoo.com/lifestyle/articles/restaurant-menus-getting-smaller-glp-160004125.html
- Mexico Business News — Novo Nordisk CEO on food industry rethink (Oct 12, 2026): https://mexicobusiness.news/health/news/glp-1-drugs-push-food-industry-rethink-portions-products
- WebProNews — GLP-1 drugs shrink appetites; food company earnings calls (Oct 12, 2026): https://www.webpronews.com/glp-1-drugs-shrink-appetites-and-grocery-bills-pharma-giants-reap-billions-while-snack-makers-scramble/
- Food Navigator — Nestlé developing GLP-1 nutrition products (Oct 8, 2026): https://www.foodnavigator.com/Article/2026/10/08/how-glp-1-weight-loss-drugs-are-reshaping-food-and-beverage-innovation/
- CNBC — Walmart $0 GLP-1s for T2D employees in 2027 (Oct 13, 2026): https://www.cnbc.com/2026/10/13/walmart-glp-1s-inhalers-employee-benefits.html
- Nature / Blood Cancer Journal — GLP-1RAs and hematologic malignancy risk, TriNetX matched cohort (Oct 12, 2026): https://www.nature.com/articles/s41408-026-01618-4
- CNN — Semaglutide extends lifespan in older mice, Nature study (Oct 13, 2026): https://www.cnn.com/2026/10/13/health/glp-1-drugs-anti-aging
- UC Berkeley — GLP-1 treatment extends lifespan in older healthy mice (Sept 2026): https://vcresearch.berkeley.edu/news/glp-1-treatment-extends-lifespan-older-healthy-mice.
- Nature — Pharma's GLP-1 brain-drug pipeline: brenipatide, KP405, Baseline Therapeutics (Oct 13, 2026): https://www.nature.com/articles/d41586-026-03252-3
- Pharmacy Times — Petrelintide Phase 2 ZUPREME-1: up to 10.7% at 42 weeks (Oct 6, 2026): https://www.pharmacytimes.com/view/petrelintide-yields-up-to-10-7-weight-loss-with-mild-gi-effects
- GlobeNewswire — Zealand Pharma: Survodutide SYNCHRONIZE-2 up to 13.1% at 76 weeks (Oct 1, 2026): https://www.globenewswire.com/news-release/2026/10/01/3372565/0/en/zealand-pharma-announces-boehringer-ingelheim-s-survodutide-achieves-up-to-13-1-weight-loss-in-new-phase-iii-trial-alongside-significant-improvements-in-glycemic-control-in-people-.html
- GlobeNewswire — Regeneron: Trevogrumab COURAGE prevents 70% of GLP-1 muscle loss (Oct 1, 2026): https://www.globenewswire.com/news-release/2026/10/01/3373155/0/en/phase-2-courage-trial-confirms-trevogrumab-prevents-lean-mass-and-muscle-loss-during-glp-1-receptor-agonist-induced-weight-loss.html
A Spoke-Media production:
https://www.spoke-media.com
5: Peptalk Deep Dive — Tesamorelin
2026/10/12
Last week: Sermorelin, the elegant idea. This week: Tesamorelin - its bigger sibling, and the evidence heavyweight of the growth hormone peptide world.
Jake and Cynthia unpack Tesamorelin — the full forty-four amino acid growth hormone releasing factor with a protective chemical cap, two Phase three trials, visceral fat down fourteen to eighteen percent, lean body mass up, liver fat down, and an FDA approval (Egrifta) with a formulation modernization: Egrifta WR, approved March 2025 and in pharmacies since September 2025.
Plus the honest limits: a narrow approved use, maintenance required, and long-term cardiovascular safety still an open file.
Also: the weekly GLP pulse — the growing evidence that GLP-1s curb drug and alcohol cravings (PBS NewsHour), plus new research on compulsive gambling and shopping (CBS News).
For research and informational purposes only — not medical advice.
Sources:
• PBS NewsHour — The evidence suggesting GLP-1s can curb drug and alcohol cravings (Oct 7, 2026): https://www.pbs.org/newshour/show/the-evidence-suggesting-glp-1s-can-curb-drug-and-alcohol-cravings
• CBS News — Doctor explains how GLP-1 drugs could help reduce gambling, shopping addiction (Oct 9, 2026): https://www.cbsnews.com/news/glp-1-drugs-wharton-study-impulsive-spending/
• Medscape — Tesamorelin reduces visceral fat in HIV-associated lipodystrophy (Phase 3 data): https://www.medscape.com/viewarticle/732450
• Theratechnologies / Drugs.com — FDA Approval for EGRIFTA WR (tesamorelin F8), March 25, 2025: https://www.drugs.com/newdrugs/theratechnologies-receives-fda-approval-egrifta-wr-tesamorelin-f8-excess-visceral-abdominal-fat-6482.html
• Theratechnologies — Availability of EGRIFTA WR, September 5, 2025: https://www.cbj.ca/theratechnologies-announces-availability-of-egrifta-wr-tesamorelin-for-injection-to-reduce-excess-abdominal-fat-in-adults-with-hiv-and-lipodystrophy/
• Stanley & Grinspoon — Effect of Tesamorelin on Liver Fat and Visceral Fat in HIV-Infected Patients With Abdominal Fat Accumulation (JAMA / PMC): https://pmc.ncbi.nlm.nih.gov/articles/PMC4363137/
• Peptpedia — Tesamorelin (Egrifta): FDA-Approved, Visceral Fat Data: https://peptpedia.org/peptide/tesamorelin
A Spoke-Media production:
https://www.spoke-media.com
4: Peptalk Week in Review — October 9, 2026
2026/10/09
This week: both Lilly and Novo converged on $499/month cash pricing — and we walk the whole price ladder from list price to TrumpRx to the gray market.
Plus: Petrelintide's Phase 2 amylin data (up to 10.7% at 42 weeks with placebo-like tolerability) and its diabetes sister trial, retatrutide's low-dose readout (12.7% at just 4 mg), Trevogrumab's muscle-preservation data (70% of MRI-measured muscle loss prevented), Survodutide's Phase 3 diabetes trial (up to 13.1%),
CagriSema's data blitz ahead of an expected October FDA decision, the WHO's first childhood-obesity guidelines vs. strong teen GLP-1 data, Orforglipron's heart-safety clearance, a compounded-glutathione recall, and two-year data on J&J's oral peptide for psoriasis.
For research and informational purposes only — not medical advice. Nothing on this show is a recommendation for any product or treatment.
**Sources:**
- The Educated Patient — Lilly + Novo reduce GLP-1 costs in the post-shortage era ($499 cash pricing): https://www.theeducatedpatient.com/view/eli-lilly-novo-nordisk-reduce-glp-1-costs-in-post-shortage-era
- Pharmaphorum — Novo Nordisk cuts GLP-1 prices for cash buyers (NovoCare): https://pharmaphorum.com/news/novo-nordisk-cuts-glp-1-prices-cash-buyers
- Retail TouchPoints — TrumpRx.gov lower-price promise (MFN pricing, GoodRx integration): https://www.retailtouchpoints.com/features/news-briefs/trumprx-gov-promises-lower-prices-on-popular-prescription-drugs
- White House fact sheet — GLP-1 Bridge Medicare program ($50 copay, 600,000 seniors): https://www.whitehouse.gov/fact-sheets/2026/09/fact-sheet-president-donald-j-trump-announces-lower-drug-prices-for-all-50-state-medicaid-programs/
- Biocare Nutrition — GLP-1 cost without insurance: https://biocarenutrition.com/blogs/biocare-blog/glp-1-cost-without-insurance.
- Dispense Times — the GLP-1 showdown: TrumpRx, compounding crackdowns, and the new era of drug pricing: https://dispensetimes.com/the-glp-1-showdown-trumprx-compounding-crackdowns-and-the-new-era-of-drug-pricing/
- Zealand Pharma announcement — petrelintide ZUPREME-1 Phase 2 data, The Lancet Diabetes & Endocrinology publication, EASD 2026 presentation: https://business.theeveningleader.com/theeveningleader/article/gnwcq-2026-9-29-zealand-pharma-to-present-additional-data-from-phase-2-zupreme-1-trial-for-petrelintide-at-easd-2026-and-announces-publication-of-trial-results-in-the-lancet-diabetes-and-endocrinology
- Reuters (Oct 7, 2026) — petrelintide ZUPREME-2 in type 2 diabetes (up to 9.2% at 28 weeks): https://www.reuters.com/business/healthcare-pharmaceuticals/zealand-roches-obesity-drug-helps-patients-lose-up-92-weight-mid-stage-trial-2026-10-07/
- Eli Lilly press release (Jul 23, 2026) — retatrutide Phase 3 (29.8 lb / 12.7% at 4 mg; FDA filing Q1 2027): https://lilly.mediaroom.com/2026-07-23-Lillys-triple-agonist,-retatrutide,-successful-in-two-additional-Phase-3-obesity-trials,-delivering-significant-improvements-in-weight-and-A1C?asPDF=1
- Regeneron press release (Oct 1, 2026) — COURAGE Phase 2 trevogrumab muscle-loss prevention (70% MRI substudy): https://www.globenewswire.com/news-release/2026/10/01/3373155/0/en/phase-2-courage-trial-confirms-trevogrumab-prevents-lean-mass-and-muscle-loss-during-glp-1-receptor-agonist-induced-weight-loss.html
- Zealand Pharma press release (Oct 1, 2026) — survodutide SYNCHRONIZE-2 Phase 3 (up to 13.1% at 76 weeks, NEJM): https://www.globenewswire.com/news-release/2026/10/01/3372565/0/en/zealand-pharma-announces-boehringer-ingelheim-s-survodutide-achieves-up-to-13-1-weight-loss-in-new-phase-iii-trial-alongside-significant-improvements-in-glycemic-control-in-people-.html
- TradingView weekly recap — HRS-1596 licensing and CagriSema 52-week EASD results: https://www.tradingview.com/news/tradingview:67ef0d4ddfa76:0-weekly-recap-hrs-1596-licensing-deal-and-cagrisema-52-week-trial-results/
- WHO — launch of guidelines on integrated management of obesity in children and adolescents (Oct 7, 2026): https://www.who.int/news-room/events/detail/2026/10/07/default-calendar/launch-of-who-guidelines--integrated-management-of-obesity-in-children-and-adolescents
- Reuters (Oct 7, 2026) — WHO endorses lifestyle changes over GLP-1 drugs in child-obesity fight: https://www.reuters.com/business/healthcare-pharmaceuticals/who-endorses-lifestyle-changes-over-glp-1-drugs-child-obesity-fight-2026-10-07/
- Seoul Economic Daily (Oct 6, 2026) — ecnoglutide Phase 1b in obese adolescents (up to 12.1% at 20 weeks): https://en.sedaily.com/technology/2026/10/06/hk-innons-glp-1-obesity-drug-cuts-teen-weight-up-to-121
- Pharmacy Times (Oct 1, 2026) — orforglipron ACHIEVE-4 CV safety vs. insulin glargine: https://www.pharmacytimes.com/view/orforglipron-shows-cv-safety-vs-insulin-glargine-in-achieve-4
- USA Today (Oct 2, 2026) — Greenwich Rx compounded-glutathione recall: https://www.usatoday.com/story/money/consumer-protection/recalls-alerts/2026/10/02/injectables-drugs-recalled-greenwich-rx/92055116007/
- Johnson & Johnson press release (Oct 2, 2026) — ICOTYDE (icotrokinra) 2-year ICONIC-TOTAL data, EADV 2026: https://www.jnj.com/media-center/press-releases/johnson-johnson-announces-new-icotyde-icotrokinra-data-in-difficult-to-treat-plaque-psoriasis-with-proven-durability-through-2-years-affirming-its-use-as-a-powerful-first-line-systemic-therapy
A Spoke-Media production:
https://www.spoke-media.com
3: Peptalk Deep Dive — Sermorelin
2026/10/05
Sermorelin is having a moment.
Jake and Cynthia unpack the growth hormone peptide everyone's pivoting to: what it is (a copy of your body's own GHRH signal), how it works (pulsatile, feedback-intact), what the research actually shows (nocturnal GH up, lean mass up in men, skin thickness up in both sexes), and why it's trending now that ipamorelin is restricted. Plus its surprising pedigree: an FDA-approved drug (Geref, 1997) that left the market for business reasons, not safety. Honest bottom line included.
Also: the weekly GLP pulse — Retatrutide goes mainstream, CagriSema food-noise data, and a $2.6B oral GLP-1 deal.
For research and informational purposes only — not medical advice.
Sources:
• Prime Lab Peptides — sermorelin pituitary signaling (Khorram 1997): https://primelabpeptides.com/blogs/news/how-does-sermorelin-influence-pituitary-signaling-pathways-in-endocrine-research
• Sermorelin myths vs. reality (Geref 1997/2008, 503A compounding): https://medium.com/@esochabiakasikhi/sermorelin-peptide-myths-vs-reality-bdeea758b588
• Scientific American — growth hormone peptides and the evidence: https://www.scientificamerican.com/article/growth-hormone-peptides-promise-to-stall-aging-but-does-the-science-stack-up/
• The BMJ — retatrutide TRIUMPH Phase 3: http://www.bmj.com/content/395/bmj-2026-101016
• Pharmacy Times — CagriSema curbs food noise: https://www.pharmacytimes.com/view/cagrisema-curbs-food-noise-organ-fat-in-patients-with-obesity-t2d-respectively
• Business News Today — Novo–Hengrui $2.6B deal: https://business-news-today.com/hengrui-lands-2-6bn-novo-nordisk-deal-for-experimental-weekly-oral-obesity-drug/
A Spoke-Media production:
https://www.spoke-media.com
2: Peptalk Week in Review — October 2, 2026
2026/10/02
EASD 2026 in Milan turned into a Lilly showcase — and Jake and Cynthia round up the whole week.
Stories this week:
(1) Retatrutide's full Phase 3 TRIUMPH-1 data — up to 25% weight loss at 80 weeks, plus knee osteoarthritis and sleep apnea improvements — and TRIUMPH-2 in type 2 diabetes published in The Lancet; Lilly expects to file with the FDA by end of March 2027.
(2) Lilly's amylin + tirzepatide combo EloraTZP: 23.3% at 48 weeks heading to Phase 3, with a real tolerability question — plus the wider amylin stacking moment.
(3) Boehringer/Zealand's survodutide Phase 3 SYNCHRONIZE-2: 13.1% at 76 weeks, published in NEJM the same day.
(4) Novo's oral strategy: up to $2.6B for ex-China rights to Hengrui's weekly oral GLP-1/GIP, real-world data on switching to the Wegovy pill, and Wegovy liver-fat normalization.
(5) The FDA's warning letter to Empower Pharmacy over mass-produced compounded GLP-1s — its fourth. Plus a market check: LLY dipped on great news, NVO down ~24% YTD.
For research and informational purposes only — not medical advice.
**Sources:**
- Cardiac Wire — TRIUMPH-1 full Phase 3: https://cardiacwire.com/a-new-king-of-the-glp-1s-could-be-crowned/
- USA Today — TRIUMPH-2 / Lilly FDA filing plans: https://www.usatoday.com/story/money/personal-finance/healthcare/2026/09/30/retatrutide-glp-1-eli-lilly-weight-loss/92019663007/
- BioSpace — EloraTZP Phase 2b: https://www.biospace.com/drug-development/superior-weight-loss-blood-sugar-control-propel-lillys-amylin-gip-glp-1-combo-into-phase-3
- Zealand Pharma — SYNCHRONIZE-2: https://mfn.se/one/a/zealand-pharma/zealand-pharma-announces-boehringer-ingelheims-survodutide-achieves-up-to-13-1-weight-loss-in-new-phase-iii-trial-alongside-significant-improvements-in-glycemic-control-in-people-with-obesity-and-type-2-diabetes-a9e0d011
- Business News Today — Novo–Hengrui $2.6B deal: https://business-news-today.com/hengrui-lands-2-6bn-novo-nordisk-deal-for-experimental-weekly-oral-obesity-drug/
- Reuters — OCTANE real-world switching study: https://www.reuters.com/legal/litigation/patients-switching-to-novo-nordisks-wegovy-pill-shots-lose-more-weight-real-2026-09-30/
- Becker's Hospital Review — FDA warning letter to Empower Pharmacy: https://www.beckershospitalreview.com/pharmacy/fda-flags-sterility-concerns-at-major-glp-1-compounder/
A Spoke-Media production:
https://www.spoke-media.com
Peptalk Pilot: Deep Dive — NAD+
2026/09/30
Welcome to Peptalk! In our pilot episode, Jake and Cynthia go deep on NAD+ (nicotinamide adenine dinucleotide) — one of the most talked-about molecules in the peptide world right now, even though it's not technically a peptide at all.
We open with a fast GLP-1 pulse: retatrutide's showstopping EASD 2026 data (28.3% weight loss at 80 weeks), a warning about gray-market vials, Lilly's oral orforglipron vs. oral semaglutide, and Novo's deal with Nanexa on long-acting delivery.
Then the deep dive: what NAD+ actually does in the body (mitochondrial energy, sirtuin activation, DNA repair), the formats it's sold in (IV drips, injections, oral NR/NMN precursors, nasal spray), and what a 2026 systematic review really found — precursors reliably raise blood NAD+ metabolites, but functional outcomes are mixed, and there are zero clinical trials of IV NAD+ for wellness. Plus the cell-membrane problem, the GLP-1 stacking rationale, safety data, and an honest bottom line.
For research and informational purposes only — not medical advice.
**Sources:**
- StackTrax NAD+ guide: https://stacktrax.com/guides/nad-plus
- Frontiers in Aging — IV NAD+ and precursors in wellness: https://www.frontiersin.org/journals/aging/articles/10.3389/fragi.2026.1887175/full
- NPR/WAMC — "Marketers say NAD+ pills and infusions can boost longevity. What's the evidence?": https://www.wamc.org/2026-05-11/marketers-say-nad-pills-and-infusions-can-boost-longevity-whats-the-evidence
- Key Wellness — NAD+ therapy research summary: https://www.keytwellness.com/post/nad-therapy-cellular-energy-and-what-the-research-shows
- Abby Langer — "The NAD+ Anti-Aging Hype, Explained": https://bitemebyabbylanger.substack.com/p/can-nad-really-slow-aging
- Medical Daily — EASD 2026 retatrutide data preview: https://www.medicaldaily.com/easd-2026-retatrutide-mounjaro-wegovy-pill-data-preview-479203
- Morningstar/PR Newswire — Lilly's orforglipron vs. oral semaglutide: https://www.morningstar.com/news/pr-newswire/20260929de57460/lillys-foundayo-orforglipron-172-mg-showed-greater-weight-loss-and-a1c-reduction-than-oral-semaglutide-25-mg-among-adults-with-type-2-diabetes-in-a-new-indirect-treatment-comparison
A Spoke-Media production:
https://www.spoke-media.com
Podcast sponsorship advertising
Start advertising on PEPtalk relevant audience podcasts
You may also like to advertise on these Podcasts

4.7833521
The Home Service Expert Podcast
Tommy Mello: $200 Million Founder|Forbes, Inc., Entrepreneur Columnist

4.443621369
Something You Should Know
Mike Carruthers | OmniCast Media

4.7906254
Everything is Fine
Jennifer Romolini and Kim France

4.610912581
Serialously with Annie Elise
Annie Elise & Audioboom Studios

4.41171483
The Outlier Health Podcast
Matt Frazier, Matt Tullman, Isabelle Caputo, and Doug Hay

4.616215365
Giggly Squad
Hannah Berner & Paige DeSorbo

4.8219787
Imperfect Action
Steph Taylor

4.727630592
This Past Weekend w/ Theo Von
Theo Von

4.713049379
The Tim Dillon Show
The Tim Dillon Show

4.116091470
The Tucker Carlson Show
Tucker Carlson Network